C-WRZLOrigami Therapeutics
protein degradation, small molecules, neurodegeneration
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-WRZL
C-WRZLC-WRZLprotein degradation, small molecules, neurodegeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
How does the Origami Therapeutics × Ipsen collaboration advance treatments for rare neurodegenerative diseases? In this clip from ExtraMile by YourTechDiet, Dr. Beth Hoffman, President & CEO of Origami Therapeutics, shares how this partnership is accelerating research and unlocking new possibilities in drug discovery.
How can protein degrader technology target disease-causing proteins? In this clip from ExtraMile by YourTechDiet, Dr. Beth Hoffman, President & CEO of Origami Therapeutics, explains how this approach works and why it holds promise for treating neurodegenerative diseases. #OrigamiTherapeutics #BethHoffman #Biotech #DrugDiscovery #NeurodegenerativeDiseases #LifeSciences #healthcareinnovation
The newest session of ExtraMile by YourTechDiet features Dr. Beth Hoffman, the President and CEO of the leading preclinical-stage biopharmaceutical company, Origami Therapeutics. The firm has been developing best-in-class therapeutics for neurodegenerative diseases to address diseases that cause proteins in neurodegenerative disorders. Such diseases include Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and others. Origami focuses significantly on Huntington’s Disease. Dr. Beth Hoffman is a seasoned drug discovery scientist who created a new approach to discovering curative medicines for neurodegenerative diseases with the establishment of Origami Therapeutics. Join us in this conversation and discover the most important elements contributing to successful drug discovery, the challenges faced by researchers in turning early-stage discoveries into a clinical Proof-of-Concept, and more. Watch the full interview and subscribe to our channel
Get inspired by a powerhouse panel of female founders sharing their journeys, challenges, and game-changing innovations at the Galentine’s Day Founder Panel 2024! 🌟 From biotech and AI to childcare solutions and financial empowerment, these women are reshaping industries and breaking down barriers in entrepreneurship 📅 Featured Speakers: MyPhuong Le, PhD Le (Moderator) Priscilla Luckhurst MSF, MBA (MC) Olivia Rutman, CTP – Kids Care Finder Kate Lynch – NeoLaunch Cheryl K Goodman – AskTuring.ai Beth J Hoffman, PhD – Origami Therapeutics, Inc. Meg ferrigno, PhD – MoonPads Jessica Zoraida Entrepreneur, Speaker, Angel Investor – Big Picture Results Inc. 💬 What challenges have you faced as a founder? Share your thoughts below & let’s support women-led innovation! 💡 #WomenInVenture 🔔 Subscribe for more inspiring founder stories! Stay connected: Website: https://www.aquillius.com Instagram: / aquilliuscorporation LinkedIn: / aquillius LinkTree: https://linktr.ee/aquillius
The use of protein degraders is a promising area of emerging small molecule therapies. Rather than inhibit disease-causing proteins, degraders use a natural cellular process to break them down. Origami Therapeutics is using its proprietary drug discovery platform to develop novel protein degraders to target neurodegenerative diseases. The approach allows the company to target proteins that are considered undruggable because they lack an identified binding site. We spoke to Beth Hoffman, founder and CEO of Origami, about its platform for developing degraders, its focus on neurodegenerative diseases, and how its looking to potential partners to exploit the full potential of its platform technology.
Origami Therapeutics - Creative Destruction Lab Unlocking Enterprise Productivity Through AI: CDL’s Putting AI to Work Program × About Program Streams Locations Staff Putting AI to Work CDL Research Streams Prime (General) Advanced Therapies AgriFood Artificial Intelligence Biomedical Engineering BioTech Cancer Climate Computational Health Compute Defence Digital Society Energy Health Health & Wellness Healthcare Robotics Manufacturing Minerals Neuro Next Gen Computing Oceans Quantum Risk Space Supply Chain Web3 Locations Berlin Calgary Cleveland Doha Estonia Halifax London Melbourn … xas Toronto Vancouver Wisconsin Mentors Companies Partners Blog Community EN FR Apply About Program Streams Locations Staff Putting AI to Work CDL Research Streams Prime (General) Advanced Therapies AgriFood Artificial Intelligence Biomedical Engineering BioTech Cancer Climate Computational Health Compute Defence Digital Society Energy Health Health & Wellness Healthcare Robotics Manufacturing Minerals Neuro Next Gen Computing Oceans Quantum Risk Space Supply Chain Web3 … xas Toronto Vancouver Wisconsin Mentors Companies Partners Blog Community EN FR Apply Site: CDL-Toronto Cohort Year: 2021/22 Stream: Neuro origamitherapeutics.com Origami Therapeutics Origami is discovering oral drugs to halt neurodegeneration. Their approach involves eliminating the toxic proteins that are the underlying cause of neurodegeneration using protein degraders to restore normal function. Origami’s discovery platform leverages our proprietary human disease models t
RePORT ⟩ RePORTER We're sorry but RePORTER doesn't work properly without JavaScript enabled. Please enable it to continue.
Origami Therapeutics Funding | $1-5M Revenue | Complete Analysis | Extruct AI Studio Work Customers Customer stories from teams running on Extruct Research Market analyses, batch reports, theses Data Room Public datasets, indexed live Product Pricing Plans and credits for the product API Docs Build on the Extruct API Product Blog Releases, how-tos, field notes Work Customers Research Data Room Product Pricing API Docs Product Blog Book a call Login Loading company information... Product Home Studio Pricing API Docs System Status Resources Documentation How to Start Blog Customers Data Accuracy
Origami Therapeutics, Inc. selected as a CONNECT 2020 Cool Company Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gal … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
June | 2020 | Next Phase Newsletter Life Science Nation Next Phase Newsletter Search Next Phase Newsletter Home Hot Mandates Previous Issues Podcast Subscribe Archive | June, 2020 Check Out the Digital RESI September 14 – 16 Agenda 25 Jun By Karen Deyo, Senior Investor Research Analyst, LSN RESI is continuing to improve our digital events, adding features and content to increase the efficiency of interactions between investors and fundraising company CEOs. While RESI is a partnering-focused conference, the panel and workshop content offer key insights for startup CEOs, helping them … e able to listen in to live sessions during the conference, with the ability to submit questions for Q&A. Make sure to register to gain access to this valuable content. Share this: Share on X (Opens in new window) X Share on LinkedIn (Opens in new window) LinkedIn Share on Facebook (Opens in new window) Facebook Email a link to a friend (Opens in new window) Email Print (Opens in new window) Print Like Loading... Comments Leave a Comment Categories Redefining Every Stage … en self-funded thus far. We are currently seeking Seed funding and non-dilutive grant funding. EW: Enter RESI. How has LSN and RESI been helping to get you in front of investors? Please describe the coaching and what you have learned. BH: First, I have to credit Women in Bio and their efforts to get us engaged with the WIB Pitch Competition and the Innovation Challenge. I would not have been likely to become engaged with RESI without the WIB engagement and pricing discounts. … portfolio companies to achieve strategic goals efficiently. The partners of the fund have combined decades of drug industry experiences before establishing the firm in 2019. The fund invests in true innovations with a major impact on patients’ lives. The firm’s investment size can range from $1 M and up to $6 M, in which the typical size would be $3 M~$4 M. The firm is actively looking for new investment opportunities in North America and Europe. The firm can act … icant follow-on capability. The firm is now investing with two funds; the first fund is dedicated to investing in companies based in the Paris region across various sectors (digital, deeptech, life science), while the second fund is dedicated to investing in Digital Health companies in Western Europe. The firm generally invests between 0.3-1.5M E
Springboard Corner: Early Spring 2026 - Connect Foundation Springboard Corner: Early Spring 2026 - Connect Foundation Skip to content Companies Investors Visionaries Resources About SBDC Companies Investors Visionaries Resources About SBDC Companies Investors Visionaries Resources About SBDC Companies Investors Visionaries Resources About SBDC Facebook-f Instagram X-twitter Linkedin Youtube Springboard Corner: Early Spring 2026 March 4, 2026 5:00 am Springboard Welcome To The Springboard Corner This is your go-to spot for the latest achievements in the life sciences and high-tech startups sphe … e two companies were recently recognized with the 2025 IoT Platforms Leadership Award from IoT Evolution World . IoT Evolution World is the preeminent online publication on all things related to IoT technologies. The company had announced a strategic partnership with Identiv last year, to jointly develop specialized IoT solutions. This award is in recognition of their innovative cold chain tracking solution. (Highlighted in July 2025) The Springboard Corner Is Powered
Origami Therapeutics, Inc. Selected as a CONNECT Cool Company of 2021 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions P … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Origami Therapeutics, Inc. Selected as a CONNECT Cool Company of 2021 May 4, 2021 | 3 min read Twitter LinkedIn Facebook Email Print Origami Therapeutics http://origamitherapeutics.com , a discovery-stage company taking a precision medicine approach to discover disease-modifying treatments for neurodegener … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Origami Therapeutics, Inc. selected as a CONNECT 2020 Cool Company - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pres … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Origami Therapeutics, Inc. selected as a CONNECT 2020 Cool Company June 8, 2020 | 2 min read Twitter LinkedIn Facebook Email Print Origami Therapeutics http://origamitherapeutics.com , an early stage biotech company taking a precision medicine approach to find disease-modifying treatments for neurodegenera … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Origami Brings Protein Degradation to Neurodegenerative Disorders - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Origami Brings Protein Degradation to Neurodegenerative Disorders March 31, 2022 | 4 min read | Gail Dutton Twitter LinkedIn Facebook Email Print Origami’s precision technology platform, Oricision™, is focused on diseases that affect the central nervous system rather than … most often is used in oncology. Now, Origami Therapeutics is among the first to apply it to genetic neurodegenerative disorders, targeting proteins that otherwise have been considered undruggable. “In neurodegeneration, there are proteins that have become toxic in the cell, and we want to get rid of them,” Beth Hoffman, Ph.D., founder, president and CEO of Origami, told BioSpace. “Protein degraders are a way to remove specific proteins that are causing disease.” Origami’s app … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Business Big Pharma restructures to ride out ‘existential risk’ June 24, 2026 · 10 min read · Tristan Manalac " href="https://www.biospace.com/deals/lilly-astellas-circle-sangamo-assets-as-biotech-files-for-bankruptcy" > Bankru … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
5th Advancing Women's Leadership Skills in Pharma & Healthcare - Dynamic Global Events Browse Other Conferences Home Agenda Speakers Venue Sponsorship Become a Speaker Register Browse Other Conferences Home Agenda Speakers Venue Sponsorship Become a Speaker Register Browse Other Conferences Home Agenda Speakers Venue Sponsorship Become a Speaker Register Conference Schedule Download Detailed Agenda Day 1 Day 2 8:00 AM - 8:45 AM LOGIN 8:45 AM - 9:00 AM OPENING REMARKS 9:00 AM - 9:45 AM Sponsorship, Salary Equity, and Cultivating the Success of Women Who Lead Despite equal numbers of wo … r. Andrews will address the latest research on these topics and show you how to apply practical strategies to boost your career and maximize talent in your organization. Speaker: Shawn Andrews Founder & CEO Andrews Research International 12:45 PM - 1:00 PM BREAK 1:00 PM - 2:00 PM ROUNDTABLE: Strategies for Leading Multi-Generational, High Performing Teams Most offices today feature a multigenerational workforce, with employees ranging from Baby Boomers approaching retirem
Appreciative of this nice... - Origami Therapeutics, Inc. Facebook Log In Origami Therapeutics, Inc.'s Post Origami Therapeutics, Inc. March 4 · Shared with Public Appreciative of this nice interview of our CEO, Beth J Hoffman in the San Diego Business Journal highlighting our recent partnership with Ipsen. linkedin.com Origami inks deal with Ipsen | Origami Therapeutics, Inc. All reactions: 2 Like Comment
BioFuture™ 2025 Explores the Next Era of Innovation, Policy, and Investment in Biopharma - Demy Colton Skip to content About Who We Are What We Do Sponsorship See Our Sponsors Media Featured Resources Newsroom What We Listen To Media Contacts Connect With Us About Who We Are What We Do Sponsorship See Our Sponsors Media Featured Resources Newsroom What We Listen To Media Contacts Connect With Us BioFuture™ 2025 Explores the Next Era of Innovation, Policy, and Investment in Biopharma September 23, 2025 NEW YORK–( BUSINESS WIRE )–Demy-Colton today unveiled a dynamic agenda for its&nb … digital medicine and AI/ML companies to register to attend or apply to present . Qualified investors and media are encouraged to apply for complimentary registration. For more information about registering for the event, presenting opportunities, or sponsorships, visit www.biofuture.com and follow #BioFuture2025 on X. About Demy-Colton Demy-Colton is a leading life sciences and digital health events organization at the for
Origami Therapeutics, Inc. — YC Company Profile | Altss For Asset Classes Solutions Compare Case Studies Blog Book a demo Home / YC Companies / Origami Therapeutics, Inc. YC W22 Origami Therapeutics, Inc. Oral drugs to halt neurodegeneration origamitherapeutics.com LinkedIn Twitter About Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our proprietary human disease models developed to select the small molecules with the best ch … Preqin Altss vs PitchBook Altss vs FINTRX Altss vs Dakota Company About us Why Submit Data How we Collect Data Press Careers Contribute Submit your firm Submit a deal Submit a fund
Ipsen and Origami Therapeutics enter global collaboration and option agreement for protein degrader program
Origami Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Origami Therapeutics, Inc. Startups | Private Company | 2016 | California, United States | < 10 | origamitherapeutics.com Startups | Private Company | 2016 | California, United States | < 10 | origamitherapeutics.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Other Diseases Congenital Disorders Small molecule dru … most often is used in oncology. Now, Origami Therapeutics is among the first to apply it to genetic neurodegenerative disorders, targeting proteins that otherwise have been considered undruggable. “In neurodegeneration, there are proteins that have become toxic in the cell, and we want to get rid of them,” Beth Hoffman, Ph.D., founder, president and CEO of Origami, told BioSpace. “Protein degraders are a way to remove specific proteins that are causing disease.” Origami’s app … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Science - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page Our Science What is protein degradation? The control of protein levels is accomplished with a small molecule drug called a degrader. Degraders takes advantage of natural cellular processes where the overall outcome is the destruction of the protein by natural degradation pathways such as the proteasome and the lysosome. Degraders are different than inhibitors An inhibitor typically … ew article focuses on recent advances in human brain organoid systems and their application in disease modeling. It also discusses the limitations and future perspective of human brain organoids in modeling neurological diseases. About mHTT The mutant HTT (mHTT) protein retains normal function. Under conditions of reduced proteostasis where cell machinery is less able to keep protein properly folded, mHTT tends to unfold and misfold, leaving it susceptible to cleavage
Origami Therapeutics Partners with Ipsen on Rare Neurodegenerative Disorder Treatment | George Hebden Lee posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Co … t LucidQuest at [email protected] for tailored guidance on how these findings apply to your organization #CVC #CorporateVentureCapital #Pharma #Biotech #AIinHealthcare #DigitalHealth #GeneTherapy #CellTherapy #Oncology #Immunology #CNS #Neuroscience #RareDisease #AntibodyTherapeutics #PortfolioStrategy #HealthcareInnovation BioPharma (+ Google) Corporate Venture Capital Investment Trends: Who is leading in 2025? docs.google.com 1 Like Comment Share Copy LinkedIn Facebook X … t LucidQuest at [email protected] for tailored guidance on how these findings apply to your organization #CVC #CorporateVentureCapital #Pharma #Biotech #AIinHealthcare #DigitalHealth #GeneTherapy #CellTherapy #Oncology #Immunology #CNS #Neuroscience #RareDisease #AntibodyTherapeutics #PortfolioStrategy #HealthcareInnovation BioPharma (+ Google) Corporate Venture Capital Investment Trends: Who is leading in 2025? docs.google.com 1 Like Comment Share Copy LinkedIn Facebook X … t LucidQuest at [email protected] for tailored guidance on how these findings apply to your organization #CVC #CorporateVentureCapital #Pharma #Biotech #AIinHealthcare #DigitalHealth #GeneTherapy #CellTherapy #Oncology #Immunology #CNS #Neuroscience #RareDisease #AntibodyTherapeutics #PortfolioStrategy #HealthcareInnovation BioPharma (+ Google) Corporate Venture Capital Investment Trends: Who is leading in 2025? docs.google.com Like Comment Share Copy LinkedIn Facebook X To … t LucidQuest at [email protected] for tailored guidance on how these findings apply to your organization #CVC #CorporateVentureCapital #Pharma #Biotech #AIinHealthcare #DigitalHealth #GeneTherapy #CellTherapy #Oncology #Immunology #CNS #Neuroscience #RareDisease #AntibodyTherapeutics #PortfolioStrategy #HealthcareInnovation BioPharma (+ Google)
Index of /wp-content/themes/Divi/includes/builder/module Index of /wp-content/themes/Divi/includes/builder/module Name Last modified Size Description Parent Directory - Accordion.php 2022-09-26 08:26 17K AccordionItem.php 2022-09-26 08:26 11K Audio.php 2022-09-26 08:26 17K BarCounters.php 2022-09-26 08:26 31K BarCountersItem.php 2022-09-26 08:26 20K Blog.php 2022-09-26 08:26 72K Blurb.php 2022-09-26 08:26 38K Button.php 2022-09-26 08:26 12K CircleCo
Instagram Instagram Log In Sign Up Close Never miss a post from facccalifornia Sign up for Instagram to stay in the loop. Sign up Log in facccalifornia • Follow More options facccalifornia 11w [SAN FRANCISCO] 🧠 Beyond the Brain: The Next Frontier of Human-Machine Interaction 🚀 Brain-Computer Interfaces (BCIs) are no longer science fiction, they’re redefining how we interact with technology, restore lost function, and augment cognition. 🎤Join leading experts at the crossroads of neuroscience, engineering, and innovation for an in-depth discussion on BCI: - Philip Sabes, Co-founder, Neuralink
Index of /wp-content/themes/Divi/includes/builder/feature/dynamic-assets/assets/css Index of /wp-content/themes/Divi/includes/builder/feature/dynamic-assets/assets/css Name Last modified Size Description Parent Directory - accordion.css 2022-09-26 08:26 1.3K accordion_cpt.css 2022-09-26 08:26 1.6K animations.css 2022-09-26 08:26 16K animations_cpt.css 2022-09-26 08:26 17K audio.css 2022-09-26 08:26 4.2K audio_cpt.css 2022-09-26 08:26 5.6K audio_player-rtl.css 2022-09-26 08:26
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Instagram Instagram Log In Sign Up Close Never miss a post from mindmend.biotech Sign up for Instagram to stay in the loop. Sign up Log in Tags idea2impact mindmend.biotech • Follow More options mindmend.biotech 31w We are thrilled to share that MindMendBiotech has been accepted into VentureWell’s E-Team Program for Winter 2026! 🎉 As part of this program our team will take part of VentureWell’s entrepreneurship training workshop, mentorship network, and accelerator resources. This program will help MindMend: - Expand our mentorship network with experienced entrepreneurs and industry experts.
%PDF-1.6 %���� 169 0 obj > endobj xref 169 43 0000000016 00000 n 0000001547 00000 n 0000001724 00000 n 0000002865 00000 n 0000002900 00000 n 0000003039 00000 n 0000003178 00000 n 0000003725 00000 n 0000004302 00000 n 0000004476 00000 n 0000004639 00000 n 0000004676 00000 n 0000004790 00000 n 0000004902 00000 n 0000005311 00000 n 0000005821 00000 n 0000006031 00000 n 0000006623 00000 n 0000007260 00000 n 0000007995 00000 n 0000008705 00000 n 0000009452 00000 n 0000010192 00000 n 0000010961 00000 n 0000011625 00000 n 0000012071 00000 n 0000012156 00000 n 0000012572 00000 n 0000013098 00000 n 000 … 91�. -9ϷQ_o۹?�M�.m� �츐�:�]�a'JzF��~���#K��o����� �45�����ŒEČbX�� >stream application/postscript Web Valerie Rodriguez Adobe Illustrator 24.0 (Windows) 2021-09-10T17:52:42-07:00 2021-09-10T17:52:43-07:00 2021-09-10T17:52:43-07:00 default uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:feeae8f2-6898-8149-9b9f-852857db4377 xmp.iid:feeae8f2-6898-8149-9b9f-852857db4377 xmp.iid:39471c57-341b-b44c-b346-fe02b1f207ef xmp.did:39471c57-341b-b44c-b346-fe02b1f207ef uuid:65E6390686CF1 … 7ef 2021-08-11T13:38:59-07:00 Adobe Illustrator 24.0 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:feeae8f2-6898-8149-9b9f-852857db4377 2021-09-10T17:52:43-07:00 Adobe Illustrator 24.0 (Windows) / Web Adobe Illustrator 1 False False 8.694444 2.361111 Inches Cyan Magenta Yellow Black Default Swatch Group 0 White RGB PROCESS 255 255 255 Black RGB PROCESS 0 0 0 RGB Red RGB PROCESS 255 0 0 RGB Yellow RGB PROCESS 255 255 0 RGB … �4�/� �A�қK�`Z�鵰� :�N}8+�RF� �H������` Ȣ�`���l.�AGP⋕)��t+e�M�+ >stream application/postscript Web Valerie Rodriguez Adobe Illustrator 24.0 (Windows) 2021-09-10T17:52:42-07:00 2021-09-10T17:52:43-07:00 2021-09-10T17:52:43-07:00 default uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:feeae8f2-6898-8149-9b9f-852857db4377 xmp.iid:feeae8f2-6898-8149-9b9f-852857db4377 xmp.iid:39471c57-341b-b44c-b346-fe02b1f207ef xmp.did:39471c57-341b-b44c-b346-fe02b1f207ef uuid:65E6390686CF1 … 7ef 2021-08-11T13:38:59-07:00 Adobe Illustrator 24.0 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:feeae8f2-6898-8149-9b9f-852857db4377 2021-09-10T17:52:43-07:00 Adobe Illustrator 24.0 (Windows) / Web Adobe Illustrator 1 False False 8.694444 2.361111 Inches Cyan Magenta Yellow Black Default S
%PDF-1.7 %���� 1353 0 obj >stream h�25�T0P���w�/�+Q0��,H��/-���K-��0� � endstream endobj 1354 0 obj >stream h��oo���Q��]^�"g��ppg7�Ѹ1�*�� (KNTĒ!)@�����KRJ"[+g/r^N��.9;��> �C�E%*b�/l�D��������*#�Cp�e�*)U崥J�����Y!��5Rd�� Xy��)Ϫ���H�+"�����-� 9nE ) �"� )�c9��;�� iF�����!Y�U�-�C WO�hH(� �����4e���������|x_O��������WNf�g�����8$.Zh�|��/ ��/��e�� W�h^��K Y&9�� \���W�撚瓬 s�5deYG�B6Qv�m�}e�G���K�i��`u� ��J�@�|�C-4�A(b������r�|տ8}� �?.�g7�������x���Uu~�G�"�|7 M�oq��]8���� j@�$� :%��0L۔�aڥ�G��@��� #S5d(%PE&�:2���$֘dޒ1� ْx7�$�rТR��d^���� c�kl6��d4�d��� i�M0 … [ =I��M^V=� �����f@� @Ī� ��;��G > endobj 43 0 obj > endobj 44 0 obj >stream application/pdf Grid 2024-09-05T08:33:16-04:00 2024-09-05T08:33:16-04:00 2024-09-05T08:33:16-04:00 Adobe Illustrator 28.5 (Macintosh) uuid:a45cc850-726a-e948-81fc-e6964cb4af09 xmp.did:ffeeb935-363f-4e82-8e9d-2e7c2a2ee462 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:7714bbb3-cb4b-9e4b-a7cc-ba1f08c54dbc xmp.did:09a6dae5-d973-4c6c-9883-0fe9bfce3a2a uuid:5D20892493BFDB11914A8590D31508C8 proof: … 6fb9331ee5 xmp.id:e3a0ef8f-7ea7-42a3-9834-bdf446dee1b8 proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign 19.5 (Macintosh) / 2024-10-10T09:33:27-04:00 xmp.iid:f495218a-0f5a-40d5-80b8-3cc2d7640610 xmp.did:d8f0d45f-222b-44ee-b1c0-716fb9331ee5 xmp.did:d8f0d45f-222b-44ee-b1c0-716fb9331ee5 default application/pdf Adobe PDF Library 17.0 False endstream endobj 177 0 obj > endobj 178 0 obj >stream H��W[o�6~ �� �/0I$%ْ`H�& Z�� l�SA��-T5����� � G�$�B� … 姲i��0�W%���K�%��s�� endstream endobj 215 0 obj > endobj 216 0 obj >stream application/pdf Visio-SankerIP Advertisement.vsdx DavidSanker PScript5.dll Version 5.2.2 2024-09-20T08:43:54-04:00 2024-08-21T17:28:42-07:00 2024-09-20T08:43:54-04:00 Acrobat Distiller 24.0 (Windows) uuid:6795918e-d766-423d-8f3b-3cc7f4801984 uuid:2be7dc30-eacf-054f-9ca5-78223d8e4c49 proof:pdf 1 True False 595.219971 842.000000 Pixels ArialMT Arial Regular Open Type Version 5.01.2x False Arial.ttf … 6fb9331ee5 xmp.id:e3a0ef8f-7ea7-42a3-9834-bdf446dee1b8 proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign 19.5 (Macintosh) / 2024-10-10T09:33:27-04:00 xmp.iid:f495218a-0f5a-40d5-80b8-3cc2d7640610 xmp.did:d8f0d45f-222b-44ee-b1c0-716fb9331ee5 xmp.did:d8f0d45f-222b-44ee-b1c0-716fb9331ee5 default application/pdf Adobe P
Parallel18 - Rise of The Rest’s main event in Puerto Rico... Facebook Log In Parallel18's Post Parallel18 May 3, 2019 · Shared with Public Rise of The Rest’s main event in Puerto Rico is about to start! #P18Startups PRoduce , CINCO Engineering, AgroBeads, Abartys Health and BUREA are six of the eight finalists who are about to pitch their innovative solutions for a chance to get US $100K in investment. Best of luck to all! #ROTR8 All reactions: 22 4 comments 2 shares Like Comment Most relevant Alicia Vidot Wao.... muy bendecidos como padres de Dolmarie Mendez Vidot. Felicidades a todo el
Top cystic fibrosis drug companies | VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms o … go, Calif., Arcturus Therapeutics is poised to become an industry leader in the application of RNAi technologies for the treatment of disease and improved quality of life. The company's aim is to develop... http://www.ArcturusRx.com Arrowhead Pharmaceuticals Publicly Traded Founded 2004 USA Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of deliv … om Create a Free Account to access Downloads View More With A Free Account Submit or Claim Your Company Register for Free How to Increase your Company's exposure OR Create an Account for More Register for Free View Pricing for full Business Subscription OR More about VentureRadar VentureRadar Database VentureRadar Services VentureRadar for Companies Terms & Conditions Privacy Policy Cookie Policy Copyright ©2024 VentureRadar. All Rights Reserved. Upgr … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an account with VentureRadar Refresh (When Cookies Enabled) Return to home page Create a Free Account to Follow Companies To continue, pleas
Instagram Instagram Log In Sign Up Close Never miss a post from letsdesignforyou Sign up for Instagram to stay in the loop. Sign up Log in letsdesignforyou • Follow More options letsdesignforyou 4w Let’s Design For You was proud to be a sponsor and exhibitor at this incredible event, connecting with innovators, researchers, professionals, and community leaders working to advance neurodivergent support solutions through science, technology, and creativity. From powerful expert panels to meaningful conversations at our booth, this event reminded us how important innovation, visibility, and colla
Huntingtons Disease - Origami Therapeutics Pipeline Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page Pipeline Pipeline Origami is a Pioneer in Targeted Precision Protein Folding Modulation Origami Therapeutics is a biopharmaceutical company developing novel protein degrader therapeutics and conformation correctors to treat disease in powerful new ways. Our degrader molecules harness the body’s natural protein degradation system to selectively degrade disease-ca
Origami Therapeutics | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Origami Therapeutics Website: Origami Therapeutics Business Area(s) Rare Diseases Small Molecules Therapeutics Drug Discovery Genetic Disease Protein Degradation Neurological Disease Description The company is working to discover treatments for neurodegenerative diseases caused b
561 Therapeutics Companies Worldwide | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Therapeutics 3 Employers in 3 locations Employers working on Therapeutics and Genetic Disease Reload Therapeutics | View Genetic Disease Visit the Job Board Locale World USA Careers Any Yes Internships Any Yes Displaying 1 - 3 of 3 employers Only three business areas are li
Ipsen and Origami Therapeutics Announce Protein Degrader Partnership – 24/7 BIOPHARMA Skip to content TWENTYFOURSEVENBIOPHARMA x linkedin youtube email TWENTYFOURSEVENBIOPHARMA HOME LIFE SCIENCES VIDEOS PODCASTS PHOTO LIBRARY ADVERTISE ABOUT US SUBSCRIBE Life Sciences Ipsen and Origami Therapeutics Announce Protein Degrader Partnership 30th January 2026 Ipsen and Origami Therapeutics, a biotech company developing small-molecule protein degraders and conformation correctors, announced a global collaboration and option agreement on January 30th, 2026. According to a company press release,
TPDCo directory Home Our Services About us Latest news TPDCo Directory Inspiration Publications Privacy policy Our Services About us Latest news TPDCo Directory Inspiration Publications Privacy policy TPD & Induced-Proximity Company Directory This is my subjective list of the biotechs who are focused mainly or solely in pushing their own therapeutic pipelines of TPD & induced-proximity drugs. For details on how this list was compiled, see notes at end. Targeted Protein Degradation (TPD) company directory Also now including other Induced Proximity & Bifunctional Therapeutics-Focused … erth.bio https://www.oerthbio.com/ Joint venture between Arvinas & Bayer to apply TPD methods to agri applications though presumably will need ultra high potency to keep cost of good down and won't be spraying IMiD derivatives on fields? Orionis Biosciences https://orionisbio.com/ Mainly cytokine-based therapies but expanding into glues in partnership with pharma Origami Therapeutics https://origamitherapeutics.com/ Claim to have platform able to identify protein stabiliz … a cluster of German universities, led out of Frankfurt, focused on therpaeutic application of TPD Proximity Therapeutics no website yet, stealth mode Stealth so no details except maybe neuro focus - input from some big hitters in the Boston TPD ecosystem Proxygen https://proxygen.com/ Rational glue "hunting" from Austria with leading academics as founders./advisors Ranok Therapeutics https://www.ranoktherapeutics.com/ Enigmatic TPD company advancing unique chaperone-recruiti
Thermo Fisher Scientific Opens Bay Area Cryo-EM Drug Discovery Center | Alex Runner posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign
Origami Therapeutics CEO on Neurodegenerative Disease Research | YourTechDiet posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y … post This week in San Diego life sciences: 🧠 UC San Diego received a $13M CIRM award to study the role of RNA pollution in neurodegenerative diseases. 💊 Crinetics Pharmaceuticals received European Commission approval for paltusotinib to treat acromegaly in adults. 🧬 Kyowa Kirin, Inc.- U.S. and Kura Oncology, Inc. initiated a Japanese Phase 2 registration directed trial of ziftomenib in relapsed or refractory NPM1 mutant AML. Subscribe to receive the next newsletter in your
Life Biosciences has been named one of... - David A. Sinclair Facebook Log In David A. Sinclair's Post David A. Sinclair April 27 · Shared with Public Life Biosciences has been named one of TIME’s 10 Most Influential New Frontiers Companies of 2026, along with IBM and SpaceX This reflects years of work by a dedicated and focused team From left to right: Dr. Michael Ringel (COO), Dr. Sharon Rosenzweig-Lipson (CSO), and Jerry McLaughlin (CEO). Not pictured: Amit Shashank (CAO), Ivan Kaplan (VP General Counsel) and my co-founder and founding CEO, Tristan Edwards Grateful to the scientists, c
Instagram Instagram Log In Sign Up Close Never miss a post from downtownnola Sign up for Instagram to stay in the loop. Sign up Log in downtownnola • Follow More options downtownnola 32w BioChallenge Pitch Competition Awards Grand Prize Five cutting-edge neurotechnology startups took the stage last week at the @neworleansbio ’s annual BioChallenge, competing for a combined $100,000 in non-dilutive cash prizes. The competition, held at 1441 Canal Street, celebrated global innovation in neuroscience, a field that impacts the lives of one in three people worldwide, according to the World Health O … udge deliberation, @junebraininc emerged as the winner, securing both the Grand Prize and the Audience Favorite Award. Origami Therapeutics earned runner-up honors, while Centron Bio claimed third place. Hosted by NOBIC, BioChallenge highlights the organization’s mission to cultivate and accelerate life sciences startups through access to funding, facilities, mentorship, and community. Each year’s participants gain access NOBIC’s growing network of innovators making tangible
Origami Therapeutics named finalist in BIO International Convention | Catalytic Impact Foundation posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue t
Selected as Finalist in Bio International Convention 2025 Start-up Stadium - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page Selected as Finalist in Bio International Convention 2025 Start-up Stadium Jun 22, 2025 Origami Therapeutics was selected as a Finalist at the Start-Up Stadium at BIO 2025! Search Search Recent Posts Targeting protein misfolding in neurodegeneration What To Look For In Rare Disease Partnerships, With Origami’s
Panelist at Bio International Convention 2025 - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page Panelist at Bio International Convention 2025 Jun 16, 2025 Beth J. Hoffman, PhD, Founder and CEO of Origami Therapeutics, Inc. was a panelist for: Next-Generation Alzheimer’s Disease Therapies As the search for effective treatments for Alzheimer’s disease intensifies, join us for a compelling panel discussion on the next-generation therapi
Origami Therapeutics named an Innovation Challenge Finalist at upcoming Digital RESI June Conference - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page Origami Therapeutics named an Innovation Challenge Finalist at upcoming Digital RESI June Conference May 20, 2020 San Diego, May 21, 2020 – Origami Therapeutics has been selected as a finalist in the forthcoming Digital RESI June Conference Innovation Challenge. Companies were selected on th
ORICISION - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page ORICISION™ Drug Discovery Platform ORICISION™ Drug Discovery Platform Treating Disease in a New Way: Precision Protein Degradation and Correction Origami Therapeutics is working at the forefront of new and exciting modalities called targeted protein degradation (TPD) and targeted protein conformation correction to invent new medicines for diseases with limited or no known treatmen
Instagram Instagram Log In Sign Up Close Never miss a post from b2i_digital Sign up for Instagram to stay in the loop. Sign up Log in b2i_digital Verified • Follow More options b2i_digital Verified 12w Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a B2i Digital Featured Company, will present its clinical and commercial progress at the Emerging Growth Conference 91 on April 2, 2026, at 10:15 AM ET. The presentation will be conducted via interactive webcast, and investors, advisors, and analysts are invited to attend. See Jupiter Neurosciences’ B2i Digital Featured Companies profile: https://b2idi
o2h Kickstarter: Innovate America – Now Live! Skip to content o2h discovery website o2h discovery – seeding new ideas in life science, tech and green … about company overview team ESG o2h community how we deliver news & insights news & press releases blogs posters newsletters white papers webinars brochures events exhibiting/attending events o2h Innovation Conference 2026 Bootcamps AIM squad Cambridge Wide Open Day Cambridge TechBIO Caucus Biotech Bikers o2h Chaitime Webinar culture & careers CITC TM o2h group integrated (drug discovery) Target Identification and Val … t. Read on to learn more about our newest edition and check your eligibility to apply… Kind Regards, The Team @o2h Discovery --> About the o2h Kickstarter: Innovate America The o2h Kickstarter: Innovate America competition is designed to provide a chemistry boost to USA-based small molecule-focused biotechnology companies that have raised initial funding and need to supercharge their chemistry efforts to meet their next milestone. Winners will receive a cost-effective, dedica … ience, and Synprox. We are delighted to be back with our newest version of this award to support innovative early-stage biotech companies working on novel drug discovery programs that can ultimately benefit human health. To read more, please visit - o2h.com/o2h-kickstarter-innovate-america/ Sumbit your entry --> Some of the Winners of Earlier Kickstarter Editions --> This is an opportunity for you to 'turbocharge your biotech startup with a chemistry boost! … discovery project to the next level with o2h Discovery’s support and expertise. Apply now If you believe this opportunity could benefit your biotech network, we encourage you to share it with them. Refer to a Biotech Friend --> About o2h Discovery: Overview & Capabilities Founded in 2005, o2h Discovery is a Contract Research Organization with an integrated drug discovery platform, operating from its state-of-the-art research center in India and The Mill SciTech Park in Ca
%PDF-1.4 1 0 obj > endobj 2 0 obj > endobj 3 0 obj > /ProcSet 6 0 R >> /MediaBox [0 0 612 792] /CropBox [0 0 612 792] /Contents 4 0 R /Thumb 11 0 R >> endobj 4 0 obj > stream q 612 0 0 792 0 0 cm /Im0 Do Q endstream endobj 5 0 obj 31 endobj 6 0 obj [ /PDF /Text /ImageC ] endobj 7 0 obj > endobj 8 0 obj > stream ����JFIF���http://ns.adobe.com/xap/1.0/ Resume generated from profile LinkedIn application/pdf Resume en 2025-07-15T14:15:50Z Apache FOP Version 2.2 1.4 1 2025-07-15T14:15:50Z 2025-07-15T14:15:50Z ��C ' .)10.)-,3:J>36F7,-@WAFLNRSR2>ZaZP`JQRO��C&&O5-5OOOOOO … JFIF���http://ns.adobe.com/xap/1.0/ Resume generated from profile LinkedIn application/pdf Resume en 2025-07-15T14:15:50Z Apache FOP Version 2.2 1.4 1 2025-07-15T14:15:50Z 2025-07-15T14:15:50Z ��C ' .)10.)-,3:J>36F7,-@WAFLNRSR2>ZaZP`JQRO��C&&O5-5OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO�� �"����\ !1A"Qa26qt�����#7BRTU����Ҕ��$3�%CEGS����&45br��Vcs����d�������� ?ɢ"�"" "" … JFIF���http://ns.adobe.com/xap/1.0/ Resume generated from profile LinkedIn application/pdf Resume en 2025-07-15T14:15:50Z Apache FOP Version 2.2 1.4 1 2025-07-15T14:15:50Z 2025-07-15T14:15:50Z ��C ' .)10.)-,3:J>36F7,-@WAFLNRSR2>ZaZP`JQRO��C&&O5-5OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO�� �"����[ !1AQ"6at2q�����#7BRTU��������$3�CGSb�%5�����4Er&s��V�Dc�������� ?ɢ"�"" "" … JFIF���http://ns.adobe.com/xap/1.0/ Resume generated from profile LinkedIn application/pdf Resume en 2025-07-15T14:15:50Z Apache FOP Version 2.2 1.4 1 2025-07-15T14:15:50Z 2025-07-15T14:15:50Z ��C ' .)10.)-,3:J>36F7,-@WAFLNRSR2>ZaZP`JQRO��C&&O5-5OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO�� �"����^ !1AQ"6at2q�����#7BRTU��������3�$Gb��45CESr����%&e��Dcs'V���������� ?ɢ"�"" … JFIF���http://ns.adobe.com/xap/1.0/ Resume generated from profile LinkedIn application/pdf Resume en 2025-07-15T14:15:50Z Apache FOP Version 2.2 1.4 1 2025-07-15T14:15:50Z 2025-07-15T14:15:50Z ��C ' .)10.)-,3:J>36F7,-@WAFLNRSR2>ZaZP`JQRO��C&&O5-5OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO�� �"��
Instagram Instagram Log In Sign Up Close Never miss a post from connectinsd Sign up for Instagram to stay in the loop. Sign up Log in Tags minimed connectinsd • Follow San Diego, California More options connectinsd 305w San Diego’s latest exit! Smart insulin pen company, Companion Medical, acquired by Medtronic. Read more: https://connect.org/company/companion-medical/ #investsd Load more comments No comments yet. Start the conversation. Like 12 Comment Share Save August 14, 2020 Log in to like or comment. More posts from connectinsd See more posts Meta About Blog Jobs Help API Privacy Terms L
Origami Therapeutics - Products, Competitors, Financials, Employees, Headquarters Locations Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & … former vice president of discovery biology at Vertex Pharmaceuticals. Eli is an award-winning reporter primarily covering the tech and life sciences industries. He previously worked as the San Diego City Hall reporter for the regional wire City News Service. He has also covered public health, transportation and state and local politics in the San Francisco Bay Area for Local News Matters, the nonprofit arm of the regional wire Bay City News Service, where he also oversaw the
Collaboration Deals in Biotechnology 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptions Expert Network FA … The Jackson Laboratory The Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center The Native Antigen Company The New York Stem Cell Foundation The Parker Institute For Cancer Immunotherapy Theragen Theragent TheraPanacea Theriva Biologics Thermo Fisher Scientific ThinkCyte ThirdEye Tianjin CanSino Biotechnology Tianjin University Tiba Biotech TiumBio Tivic Health Systems T Med TMG - Tropical Melhoramento e Genética Today TCI Tolo Biotech Tome … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … nology Related Reports Biotechnology Market Report by Product Type, Technology, Application, and Region 2026-2034  Report 138 Pages April 2026 Global From €3609 EUR $3,999 USD £3,129 GBP Biotechnology Market in the US 2025-2029  Report 170 Pages January 2025 United States From €2256 EUR $2,500 USD £1,956 GBP North America Biotechnology Market Report by Product Type, Technology, Application, Countries and Company Analysis 2025-2033  Report 200 Pages Sep … on Deals in Biotechnology 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-patt
%PDF-1.6 %���� 254 0 obj > endobj xref 254 43 0000000016 00000 n 0000001600 00000 n 0000001777 00000 n 0000002918 00000 n 0000002953 00000 n 0000003092 00000 n 0000003231 00000 n 0000003794 00000 n 0000004399 00000 n 0000004573 00000 n 0000004736 00000 n 0000004773 00000 n 0000004887 00000 n 0000004999 00000 n 0000005083 00000 n 0000005533 00000 n 0000006102 00000 n 0000006318 00000 n 0000006959 00000 n 0000007634 00000 n 0000008336 00000 n 0000008996 00000 n 0000009686 00000 n 0000010370 00000 n 0000011046 00000 n 0000011716 00000 n 0000012037 00000 n 0000012685 00000 n 0000013328 00000 n 000 … o��.�wi��>*�Ri"�죹�H-��6����<>'���O� 0� �t endstream endobj 288 0 obj >stream application/postscript Web Valerie Rodriguez Adobe Illustrator 24.0 (Windows) 2021-09-10T17:52:42-07:00 2021-09-10T17:52:43-07:00 2021-09-10T17:52:43-07:00 default uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:feeae8f2-6898-8149-9b9f-852857db4377 xmp.iid:feeae8f2-6898-8149-9b9f-852857db4377 xmp.iid:39471c57-341b-b44c-b346-fe02b1f207ef xmp.did:39471c57-341b-b44c-b346-fe02b1f207ef uuid:65E6390686CF1 … 7ef 2021-08-11T13:38:59-07:00 Adobe Illustrator 24.0 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:feeae8f2-6898-8149-9b9f-852857db4377 2021-09-10T17:52:43-07:00 Adobe Illustrator 24.0 (Windows) / Web Adobe Illustrator 1 False False 8.694444 2.361111 Inches Cyan Magenta Yellow Black Default Swatch Group 0 White RGB PROCESS 255 255 255 Black RGB PROCESS 0 0 0 RGB Red RGB PROCESS 255 0 0 RGB Yellow RGB PROCESS 255 255 0 RGB … �4�/� �A�қK�`Z�鵰� :�N}8+�RF� �H������` Ȣ�`���l.�AGP⋕)��t+e�M�+ >stream application/postscript Web Valerie Rodriguez Adobe Illustrator 24.0 (Windows) 2021-09-10T17:52:42-07:00 2021-09-10T17:52:43-07:00 2021-09-10T17:52:43-07:00 default uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:feeae8f2-6898-8149-9b9f-852857db4377 xmp.iid:feeae8f2-6898-8149-9b9f-852857db4377 xmp.iid:39471c57-341b-b44c-b346-fe02b1f207ef xmp.did:39471c57-341b-b44c-b346-fe02b1f207ef uuid:65E6390686CF1 … 7ef 2021-08-11T13:38:59-07:00 Adobe Illustrator 24.0 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:feeae8f2-6898-8149-9b9f-852857db4377 2021-09-10T17:52:43-07:00 Adobe Illustrator 24.0 (Windows) / Web Adobe Illustrator 1 False False 8.694444 2.361111 Inches Cyan Magenta Yellow Black Default S
Origami and Ipsen team up to treat neurodegenerative disorder BioXconomy is part of the Informa Connect Division of Informa PLC Informa PLC | ABOUT US | INVESTOR RELATIONS | TALENT This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726. About Events Advertise Stay Updated Stay Updated Partnering Related Topics Licensing M&A Growth Strategy Recent in Partnering See All Partnering ‘I'd like it to be our secret’: Why phar
Origami Therapeutics, Inc.: Oral drugs to halt neurodegeneration | Y Combinator | Y Combinator | 30 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y
Origami Therapeutics, Inc Company Profile: Financials, Valuation, and Growth | PrivCo Sign In Create Free Account PrivCo Origami Therapeutics, Inc Origami Therapeutics, Inc San Diego, CA Watchlist Export About Financials People Deals Funding About Origami Therapeutics, Inc Company overview Origami Therapeutics, Inc is a privately-held company that operates in the biotechnology industry. Origami Therapeutics, Inc was founded in 2016. Origami Therapeutics, Inc headquarters are located in San Diego, California. Keywords Revenue Revenue EBITDA EBITDA Valuation Valuation Income Statement Line Item
Collaboration Deals in Biotechnology 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptions Expert Network FA … The Jackson Laboratory The Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center The Native Antigen Company The New York Stem Cell Foundation The Parker Institute For Cancer Immunotherapy Theragen Theragent TheraPanacea Theriva Biologics Thermo Fisher Scientific ThinkCyte ThirdEye Tianjin CanSino Biotechnology Tianjin University Tiba Biotech TiumBio Tivic Health Systems T Med TMG - Tropical Melhoramento e Genética Today TCI Tolo Biotech Tome … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … nology Related Reports Biotechnology Market Report by Product Type, Technology, Application, and Region 2026-2034  Report 138 Pages April 2026 Global From €3609 EUR $3,999 USD £3,129 GBP Biotechnology Market in the US 2025-2029  Report 170 Pages January 2025 United States From €2256 EUR $2,500 USD £1,956 GBP North America Biotechnology Market Report by Product Type, Technology, Application, Countries and Company Analysis 2025-2033  Report 200 Pages Sep … on Deals in Biotechnology 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-patt
Instagram Instagram Log In Sign Up Close Never miss a post from neurotechdavis Sign up for Instagram to stay in the loop. Sign up Log in neurotechdavis • Follow More options neurotechdavis Edited • 11w Join us for our inaugural Neurotech Business Division Case Competition 🧠✨ Come see what our teams have been building all year as they step into the role of consultants for real medtech and neurotech companies. Watch them pitch their ideas at the intersection of medicine, neuroscience, and technology. Expect real-world business frameworks, high-energy pitches, and live feedback from an incredibl
PharmaShots Weekly (Feb 09 Edition) - PharmaShots Subscribe Sign in PharmaShots Weekly (Feb 09 Edition) PharmaShots Feb 09, 2026 1 Share Cover Story Lilly’s $3.5B U.S. Manufacturing Expansion Domestic capacity, AI-enabled operations, and a $50B long-term U.S. production vision. This Substack is reader-supported. To receive new posts and support my work, consider becoming a free or paid subscriber. Subscribe Strategic Deals & Alliances Ipsen × Origami Therapeutics: Landmark neurodegeneration deal in targeted protein degradation Genentech × SanegeneBio: $1.7B-potential RNAi licensing pact Li
Collaboration Deals in Biotechnology 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptions Expert Network FA … The Jackson Laboratory The Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center The Native Antigen Company The New York Stem Cell Foundation The Parker Institute For Cancer Immunotherapy Theragen Theragent TheraPanacea Theriva Biologics Thermo Fisher Scientific ThinkCyte ThirdEye Tianjin CanSino Biotechnology Tianjin University Tiba Biotech TiumBio Tivic Health Systems T Med TMG - Tropical Melhoramento e Genética Today TCI Tolo Biotech Tome … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … nology Related Reports Biotechnology Market Report by Product Type, Technology, Application, and Region 2026-2034  Report 138 Pages April 2026 Global From €3609 EUR $3,999 USD £3,129 GBP Biotechnology Market in the US 2025-2029  Report 170 Pages January 2025 United States From €2256 EUR $2,500 USD £1,956 GBP North America Biotechnology Market Report by Product Type, Technology, Application, Countries and Company Analysis 2025-2033  Report 200 Pages Sep … on Deals in Biotechnology 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-patt
Origami CEO, Beth Hoffman, appointed to Arctoris SAB - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page Origami CEO, Beth Hoffman, appointed to Arctoris SAB Dec 20, 2020 Arctoris appoints three experienced industry executives as members of its Advisory Board. Read Article Search Search Recent Posts Targeting protein misfolding in neurodegeneration What To Look For In Rare Disease Partnerships, With Origami’s Beth Hoffman Origami Thera
💊Rapport Therapeutics, a leader in a clinical-stage biotechnology, launched less than 18 months ago and now, they’re #NasdaqListed! ⚡$RAPP’s pace reflects an urgency to find new solutions for patients struggling with neurological disorders. 🦖Recently, their team (the Rapptors!) stopped by Nasdaq to celebrate their IPO. Congrats on the milestone! | Nasdaq
%PDF-1.7 %���� 67 0 obj > endobj xref 67 60 0000000016 00000 n 0000002057 00000 n 0000002184 00000 n 0000003249 00000 n 0000003288 00000 n 0000003423 00000 n 0000003559 00000 n 0000003695 00000 n 0000004259 00000 n 0000004741 00000 n 0000005225 00000 n 0000005628 00000 n 0000005664 00000 n 0000005751 00000 n 0000005864 00000 n 0000005978 00000 n 0000006100 00000 n 0000006745 00000 n 0000007308 00000 n 0000007835 00000 n 0000008388 00000 n 0000008481 00000 n 0000008567 00000 n 0000009190 00000 n 0000009739 00000 n 0000010267 00000 n 0000010855 00000 n 0000011352 00000 n 0000011843 00000 n 00000 … cr�85ԗΛg�ԗΛg��7,�SM1�֍I|�yMI|�yKpNb�o"/� R�Mf=]ϟR_:m�SR_:m�U� �2����t� >stream application/pdf LA BEST 2021 identity_standard_092520_outline 2021-03-29T13:48:49-07:00 2021-03-29T13:48:49-07:00 2021-03-29T13:48:46-07:00 Adobe Illustrator 24.0 (Macintosh) uuid:937e4ba4-eb32-124a-9475-0c092b1b314f xmp.did:44050f85-723d-4d38-88d7-4a2cb56de24d uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:aae02a29-c785-c847-8fe2-4b497d13ec0c xmp.did:78f46fa2-122e-4a74-902c-9883ff573294 uui … 2 Adobe PDF library 15.00 endstream endobj 114 0 obj > endobj 115 0 obj >stream application/pdf UCLATechDevelopmentLogo-final 2020-01-21T13:43:47-08:00 2020-01-21T13:43:47-08:00 2020-01-21T13:39:03-08:00 Adobe Illustrator CC 22.1 (Macintosh) uuid:d78ebb1d-0829-ad4c-ab24-d5b679254a30 xmp.did:e9fd193e-86e0-4078-99fe-2117687048fb uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:d1b83d7e-9794-8f48-b833-ae9c3fb8feac xmp.did:cf670e9b-d713-4240-adb6-5fedea7e7582 uuid:5D20892493B … 0 Adobe PDF library 15.00 endstream endobj 116 0 obj > endobj 117 0 obj >stream application/postscript UCLATechDevelopmentLogo-final Robin Weisz 2020-02-18T11:18:41-08:00 2020-02-18T11:18:41-08:00 2020-02-18T11:18:41-08:00 Adobe Illustrator 24.0 (Macintosh) xmp.iid:8679ad5e-6341-4803-b438-51a99bf3d80b xmp.did:8679ad5e-6341-4803-b438-51a99bf3d80b uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:1241bc1d-92dd-42a0-8788-dd6241d77650 xmp.did:1241bc1d-92dd-42a0-8788-dd6241d … 020-01-21T13:43:56-08:00 Adobe Illustrator CC 22.1 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:8679ad5e-6341-4803-b438-51a99bf3d80b 2020-02-18T11:18:41-08:00 Adobe Illustrator 24.0 (Macintosh) / Print False False 1 7.000000 3.811869 Inches Default Swatch Group 0 White CMYK PROCESS 0.00000
Origami Therapeutics, Inc. Selected as a CONNECT Cool Company of 2021 Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
News Archives - Page 7 of 8 - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page Origami CEO, Beth Hoffman, appointed to Arctoris SAB by Jad Duncan | Dec 20, 2020 | News Arctoris appoints three experienced industry executives as members of its Advisory Board. Read... Protein Degradation Meeting October 2020 by Jad Duncan | Oct 23, 2020 | News Official Event Guide- Digital Protein Misfolding Drug Discovery Summit- Hanson... JLABS SVB Pitch Com
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
BIO International Convention | June 22-25, 2026 | San Diego Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW June 22-25 | San Diego Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung … Mary Haak-Frednscho Board Member Surrozen, Inc. Susie Harborth Founder Inspira Fund Danielle Helton Corwin Therapeutic Area Head – Neurology Dompe Christina Hochul Senior Director, U.S. Policy and Research Bristol Myers Squibb Beth Hoffman President & CEO Origami Therapeutics Nancy Hong Managing Partner HiTide Venture Capital Amy House VP Corporate Development and Communications Beacon Therapeutics Matthew Hudes CEO bdlBiologx Ashley John Director, Issue Advo
Origami Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Origami Therapeutics, Inc. Startups | Private Company | 2016 | California, United States | < 10 | origamitherapeutics.com Startups | Private Company | 2016 | California, United States | < 10 | origamitherapeutics.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Other Diseases Congenital Disorders Small molecule dru … most often is used in oncology. Now, Origami Therapeutics is among the first to apply it to genetic neurodegenerative disorders, targeting proteins that otherwise have been considered undruggable. “In neurodegeneration, there are proteins that have become toxic in the cell, and we want to get rid of them,” Beth Hoffman, Ph.D., founder, president and CEO of Origami, told BioSpace. “Protein degraders are a way to remove specific proteins that are causing disease.” Origami’s app … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Origami Therapeutics — Catalytic Impact Foundation 0 Skip to Content Home Who We Are About Us Team Foundation Advisors Ways to Give Children's Health Impact Impact Reports 2025 Impact Report 2024 Impact Report 2023 Impact Report Our Work Women's Health Initiative Children's Health Initiative Portfolio Portfolio Companies News & Events Portfolio Company News Press & Media Contact Fiscal Sponsorship Donate Open Menu Close Menu Home Who We Are About Us Team Foundation Advisors Ways to Give Children's Health Impact Impact Reports 2025 Impact Report 2024 Impact Report 2023 Impact Repo
Origami CEO, Beth Hoffman, Speaking at upcoming Leadership Skill Conference - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page Origami CEO, Beth Hoffman, Speaking at upcoming Leadership Skill Conference May 13, 2020 San Diego, May 13, 2020 – Beth Hoffman, CEO and President of Origami Therapeutics Inc has been announced as a panelist and speaker at the upcoming Advancing Women’s Leadership Skills & Opportunities In Pharma & Healthcar
Discovery & Development US - Look Back Explore our brands Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. Events In-Person & Online Events Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities. Imaging Complex Human-Relevant Models for Early Drug Discovery 25 Jun 2026 | 14:00 BST (UTC+1) | 09:00 EDT High Resolution Screening wit … ated impressive results across a wide range of healthcare tasks. 07/11/24 - The Application of RNAi Therapeutics for Cardiovascular Disease Treatment 16/10/24 - AI/ML Advancements in Drug Formulation – The Potential of Self-Driving Labs Featured Resource Discovery & Development's 25 for 25 The Discovery & Development Top 25 of ’25 eBook brings together the most impactful voices, technologies and ideas shaping early-stage drug discovery, formulation and delivery today. … nt Panel Discussion: Technological Advancements For Novel Target Discovery Application of new technologies in identifying therapeutics for novel or currently undruggable targets Utilising AI/ML Challenges & future opportunities Panellists include Giovanni Spagnolli, Chief Technology Officer, Sibylla Biotech, Ian Roberts, Senior Director, Digital Biology, Healx & Zoran Rankovic, Director, Center for Protein Degradation, The Institute of Cancer Research Pane … Region Gothenburg Panel Discussion: Breakthrough Biotech: How Research Leaders Fund The Next Big Idea How research leaders identify and support fundable biotech innovations Overcoming early-stage funding gaps in biotech startups The role of research partnerships with pharma, VCs, and industry in startup success What startups can learn from research-backed biotech wins Panellists include Christoph Rösli, Director of Research Bern, CSL Behring & Member of the … markers Enough? Beyond blood-based biomarkers? Are we any closer to a solution? Application of AI/ML Moderated by Manuela Cerina, Scientific Director – Neurodegeneration, LifeArc & Giovanna Lalli, Director of Strategy & Operations, LifeArc Panel Discussion: Automation & Robotics In Drug Discovery & Development – Where Are We Now?&
Origami Therapeutics developing treatments for neurodegenerative diseases with ML and computational chemistry - MedCity News Twitter Facebook TikTok YouTube LinkedIn RSS Subscribe via email Newsletter Signup Send Tips Webinars eBooks Open navigation MedCity News Toggle Search Close navigation News Health Tech BioPharma Devices & Diagnostics Consumer / Employer Contributors MedCity Influencers Events Bullseye INVEST Digital Health Podcasts Research Newsletters Newsletter Signup Send Tips Webinars eBooks Twitter Facebook TikTok YouTube LinkedIn RSS Subscribe via email Search for: Search MedC … ej Wojcicki, Getty Images This is a paid member feature of MedCitizens . Please submit here and join! Topics: Beth Hoffman Huntington's disease machine learning MedCitizens Origami Therapeutics Startups More from MedCity News New Partnership Aims to Lower Out-of-Pocket Costs, Even Eliminate Them In Some Cases Xella Health Emerges from Stealth to Give Women Answers the Healthcare System Hasn’t Keeping Up With Clinicians Women’s Health Is Not a Wearable Feature — It’s an O
Origami Therapeutics partners with Ipsen on rare neurodegenerative disorder treatment | Origami Therapeutics, Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By cl
Founder Spotlight #36: Beth Hoffman @ Origami Therapeutics - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page Founder Spotlight #36: Beth Hoffman @ Origami Therapeutics Mar 21, 2022 Beth Hoffman is Founder, President, & CEO @ Origami Therapeutics. She brings more than 25 years experience of CNS drug discovery and has developed over 30 assets that have advanced into the clinic in cystic fibrosis, metabolic diseases, neurology, pain, and
Partnology Biotech Leader Spotlight interview - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page Partnology Biotech Leader Spotlight interview Aug 29, 2024 Building Exciting Biotech Companies Published Aug 29, 2024 Welcome to Partnology’s Biotech Leader Spotlight Series, where we highlight the remarkable accomplishments and visionary leadership of biotech industry pioneers. This series is about showcasing the groundbreaking strides made by
Beth Hoffman, CEO of Origami Therapeutics | Partnology Skip to content Mission Team Join Us Offerings Executive Search Investment Insights Testimonials Case Studies Contact Mission Team Join Us Offerings Executive Search Investment Insights Testimonials Case Studies Contact All Insights Beth Hoffman, CEO of Origami Therapeutics Welcome to Partnology’s Biotech Leader Spotlight Series, where we highlight the remarkable accomplishments and visionary leadership of biotech industry pioneers. This series is about showcasing the groundbreaking strides made by exceptional leaders who have transformed … olding and willing to be an advisor. This was instrumental in obtaining an SBIR grant. So, my advice is to find a professor and apply for an SBIR grant as soon as possible. Why apply for an SBIR grant? Even though you don’t get a ton of money, you need some data. If you’re coming out of academia, you usually have some data. We had no data, so I couldn’t immediately go for an SBIR. The value is not just in the money but in the exercise of writing it, thinking … a plan. You also get feedback, which helps you figure out how to resubmit your grant and how to pitch your ideas. In San Diego, there are many groups that offer support on putting together slides, starting projects, and more. If you’re starting lab work, get into an incubator. The value is in the shared experience, the access to shared equipment and feedback from others doing similar work. There are numerous groups for support, and you can practice your pitch and find
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Origami Therapeutics Leverages RESI Innovation Challenge to Meet Investors | Next Phase Newsletter Life Science Nation Next Phase Newsletter Search Next Phase Newsletter Home Hot Mandates Previous Issues Podcast Subscribe Origami Therapeutics Leverages RESI Innovation Challenge to Meet Investors 25 Jun Beth J. Hoffman, Ph.D. Founder, President & CEO of Origami Therapeutics Erich White BD Manager of LSN We are always happy to share success stories from companies that have attended RESI. As a finalist in the RESI Innovation Challenge, Origami Therapeutics used that to their advantage in … en self-funded thus far. We are currently seeking Seed funding and non-dilutive grant funding. EW: Enter RESI. How has LSN and RESI been helping to get you in front of investors? Please describe the coaching and what you have learned. BH: First, I have to credit Women in Bio and their efforts to get us engaged with the WIB Pitch Competition and the Innovation Challenge. I would not have been likely to become engaged with RESI without the WIB engagement and pricing discounts. … America, With Canadian Focus Hot Investor Mandate: Global Life Science Focused Fund Invests in Therapeutics, Medical Device, Diagnostics Companies Addressing Unmet Medical Need The Needle Issue #21 Do RESI San Diego and BIO Overlap? Recent Posts RESI San Diego 2026 Program Guide Released Meet RESI Gold Sponsor RSM: Supporting Life Science Companies Through Growth and Transformation Building Investor Readiness: Watch the First Two Sessions and Join the Final Webinar Hot Inves … offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […] LSN Twitter Tweets by LSciNation Follow Next Phase Newsletter on WordPress.com Contact us +1 (617) 600-0668 [email protected] Archives Archives Select Month June 2026 (17) May 2026 (26)
Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and G … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program February 2, 2026 | 2 min read Twitter LinkedIn Facebook Email Print - Ipsen obtains exclusive option to global license a research program for a selective disease-modifying approach to neurodegenerative disea … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
About Origami - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page About Us About Us Origami Therapeutics is a preclinical-stage company developing novel protein degrader therapeutics with a proprietary drug discovery platform which holds the promise for disease-modification in neurodegenerative diseases such as Huntington’s Disease. We are pioneering the next-generation of small molecules targeting disease-causing proteins. Our Mission At Or … dical device engineering and manufacturing firm. She completed her postdoctoral fellowship at Stanford University School of Medicine in the Department of Pediatrics. Advisory Board Steven Finkbeiner, M.D., Ph.D. Steven Finkbeiner, M.D., Ph.D. Steven is Director, Taube/Koret Center for Neurodegenerative Disease Research and the Center for Systems and Therapeutics at the Gladstone Institutes, Investigator, Roddenberry Stem Cell Center and Professor, Neurology and Physiology, Un … ch Program. Dr. Finkbeiner has received numerous awards including the Lieberman Award, the Taube/Koret Prize and the Award for Outstanding Research Achievement from Nature Biotechnology. He is a member of the American Neurological Association, the Society for Neuroscience, the Society for Cell Biology and the Biophysical Society. Dr. Finkbeiner is Associate Editor of Autophagy and serves on the editorial board of the Journal of Huntington’s Disease. He earned a bachelor’s deg … neuropharmacology from the University of Utah in 1989. Following a postdoctoral fellowship at University of Washington, she remained at the Institute as Assistant Professor of Psychiatry. She joined Eli Lilly in 2003 after contributing to neuroscience drug discovery research at Pharmacia Corp. for ~10 years. Martin Eglitis, Ph.D. Martin Eglitis, Ph.D. Martin is President of Blazing Star Pharma Advisors, a boutique biotech strategic consultancy. He has over 20 years research e
Tackling Emerging Challenges in Tech-enabled Trials with Beth J Hoffman, PhD, CEO of Origami Therapeutics Podcastit Äänikirjat Tietoa Podimosta Podcastaajille Kirjaudu sisään Aloita maksutta The Spark Jaa The Spark Tackling Emerging Challenges in Tech-enabled Trials with Beth J Hoffman, PhD, CEO of Origami Therapeutics 25 min · 15. joulu 2022 Aloita maksutta Kuvaus Clinical trials are evolving to meet the needs of patients and researchers alike. However, is the industry prepared to tackle emerging challenges in tech-enabled trials? In today's episode, our guest, Beth Hoffman, CEO of Origa
Dr. Beth Hoffman on Therapeutics of Neurodegenerative Diseases About Us Resources Blogs News Articles Infographics Interviews Extra Mile – Q/A Series Extra Mile – Video Series Contact Us Subscribe Search About Us Resources Blogs News Articles Infographics Interviews Extra Mile – Q/A Series Extra Mile – Video Series Contact Us Subscribe Search About Us Resources Blogs News Articles Infographics Interviews Extra Mile – Q/A Series Extra Mile – Video Series Contact Us Subscribe Search Interviews Extra Mile By YourTechDiet Video Series Podcast EP 12 | How Is Orig … a Ph.D. in Cell Biology from the Johns Hopkins University. She was awarded the Prize of the Anna Monika Foundation for depression research. Dr. Hoffman serves on the Board of Directors for Biofrontera Inc. (NASDAQ: BFRI), the SAB for the Tau Consortium of the Rainwater Charitable Foundation and the National Board of Trustees for the Huntington’s Disease Society of America (HDSA). About Company Origami Therapeutics Origami Therapeutics is developing curative therapies that ta … t. Moving ahead, what were the scientific challenges in the way when clinically rolling out the cystic fibrosis therapies like Kalydeco, Orkambi, Symdeko, and Trikafta during your time at Vertex Pharmaceuticals? Beth: Yeah, thanks for that question. So you know, what people may not know is that it really was the insights from these CF programs that led me to plot to leverage learnings from the CF programs and start Origami Therapeutics, focusing on neurodegenerative diseases,
Tackling Emerging Challenges in Tech-enabled Trials with Beth J Hoffman, PhD, CEO of Origami Therapeutics - The Spark | Podcast on Spotify
Ep#039: Using Protein Degrader…-Personalized Medicine Podcast-Apple Podcasts تلاش کریں ہوم نیا ٹاپ چارٹ تلاش کریں 16 مارچ، 2022 35 منٹ Ep#039: Using Protein Degraders to Treat Neurodegenerative Diseases with Dr. Beth Hoffman Personalized Medicine Podcast پلے کریں In this episode we dive deep again into the topic of protein degradation and how it can be leveraged to treat neurodegenerative diseases. Our guest today is Dr. Beth Hoffman, the founder, CEO and President to Origami Therapeutics. Beth's career is a showcase of remarkable success in the biotech industry. She spent almost 25 years
CEO Beth Hoffman guest on the Personalized Medicine Podcast - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page CEO Beth Hoffman guest on the Personalized Medicine Podcast Mar 16, 2022 Listen to the Podcast Search Search Recent Posts Targeting protein misfolding in neurodegeneration What To Look For In Rare Disease Partnerships, With Origami’s Beth Hoffman Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protei
Instagram Instagram Log In Sign Up Close Never miss a post from curegrin_foundation Sign up for Instagram to stay in the loop. Sign up Log in curegrin_foundation • Follow More options curegrin_foundation 9w We’re thrilled to welcome Lundbeck as a Gold Sponsor for #GRICON26 ! Thank you for your incredible support! 🎟️ Don’t miss out! Registration for #GRICON26 deadline is tomorrow, April 23 at 5pm EST #linkinbio #linkincomments #Lundbeck #BrainHealth #GRICON26 #Neuroscience #GoldSponsor #Conference Load more comments curegrin_foundation 9w https://bit.ly/49nBinf Like Reply Like 4 Comment 1 Shar
Origami Therapeutics, Inc.: Oral drugs to halt neurodegeneration | Y Combinator Open menu About What Happens at YC? Apply YC Interview Guide FAQ People YC Blog Companies Startup Directory Founder Directory Launch YC Library Partners Resources Startup School Newsletter Requests for Startups For Investors Verify Founders Hacker News Bookface Safe Find a Co-Founder Startup Jobs Log in Apply Home › Companies › Origami Therapeutics, Inc. Origami Therapeutics, Inc. Oral drugs to halt neurodegeneration Y Combinator Logo Winter 2022 Active Biotech Therapeutics Drug discovery Company Jobs 0 http://orig
Instagram Instagram Log In Sign Up Close Never miss a post from neworleansbio Sign up for Instagram to stay in the loop. Sign up Log in neworleansbio • Follow More options neworleansbio 5w Attention #Neurotech and #BrainHealth innovators! What does BioChallenge really mean for founders + startups? Hear directly from Beth of Origami Therapeutics, last year’s 2nd place winner, and see how this opportunity can accelerate your company, expand your network, and put your innovation in front of the right people. 🚨 2026 applications are open. If you’re building the future of #Neurotech , this is your … the future of #Neurotech , this is your moment. Don’t watch from the sidelines! Apply today @ link in bio! Load more comments No comments yet. Start the conversation. Like 6 Comment Share Save May 19 Log in to like or comment. More posts from neworleansbio Carousel Clip Carousel See more posts Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية
Origami Therapeutics selected as a CONNECT 2020 Cool Company - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page Origami Therapeutics selected as a CONNECT 2020 Cool Company Jun 2, 2020 San Diego, June 2, 2020 – Origami Therapeutics, an early stage biotech company taking a precision medicine approach to find disease-modifying treatments for neurodegenerative diseases caused by protein folding, announced today it has been selected as one of t
%PDF-1.7 %���� 58 0 obj > endobj xref 58 60 0000000016 00000 n 0000002000 00000 n 0000002127 00000 n 0000003190 00000 n 0000003229 00000 n 0000003364 00000 n 0000003500 00000 n 0000003636 00000 n 0000004200 00000 n 0000004682 00000 n 0000005084 00000 n 0000005568 00000 n 0000005603 00000 n 0000005690 00000 n 0000005803 00000 n 0000005917 00000 n 0000006039 00000 n 0000006684 00000 n 0000007247 00000 n 0000007759 00000 n 0000007845 00000 n 0000008339 00000 n 0000008939 00000 n 0000009471 00000 n 0000010036 00000 n 0000010129 00000 n 0000010752 00000 n 0000011248 00000 n 0000011797 00000 n 00000 … F�YY���HI��� � z�tؽ�2{�QU�p�$=�7B��Ef��a�ٜ��m&)�� > endobj 98 0 obj >stream application/pdf LA BEST 2021 identity_standard_092520_outline 2021-03-29T13:48:49-07:00 2021-03-29T13:48:49-07:00 2021-03-29T13:48:46-07:00 Adobe Illustrator 24.0 (Macintosh) uuid:937e4ba4-eb32-124a-9475-0c092b1b314f xmp.did:44050f85-723d-4d38-88d7-4a2cb56de24d uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:aae02a29-c785-c847-8fe2-4b497d13ec0c xmp.did:78f46fa2-122e-4a74-902c-9883ff573294 uui … 52 Adobe PDF library 15.00 endstream endobj 99 0 obj > endobj 100 0 obj >stream application/pdf UCLATechDevelopmentLogo-final 2020-01-21T13:43:47-08:00 2020-01-21T13:43:47-08:00 2020-01-21T13:39:03-08:00 Adobe Illustrator CC 22.1 (Macintosh) uuid:d78ebb1d-0829-ad4c-ab24-d5b679254a30 xmp.did:e9fd193e-86e0-4078-99fe-2117687048fb uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:d1b83d7e-9794-8f48-b833-ae9c3fb8feac xmp.did:cf670e9b-d713-4240-adb6-5fedea7e7582 uuid:5D20892493B … -/��,/���Y5�A63p�B�̬֬�z} 8ff靠���I���#X� endstream endobj 102 0 obj >stream application/postscript UCLATechDevelopmentLogo-final Robin Weisz 2020-02-18T11:18:41-08:00 2020-02-18T11:18:41-08:00 2020-02-18T11:18:41-08:00 Adobe Illustrator 24.0 (Macintosh) xmp.iid:8679ad5e-6341-4803-b438-51a99bf3d80b xmp.did:8679ad5e-6341-4803-b438-51a99bf3d80b uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:1241bc1d-92dd-42a0-8788-dd6241d77650 xmp.did:1241bc1d-92dd-42a0-8788-dd6241d … 020-01-21T13:43:56-08:00 Adobe Illustrator CC 22.1 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:8679ad5e-6341-4803-b438-51a99bf3d80b 2020-02-18T11:18:41-08:00 Adobe Illustrator 24.0 (Macintosh) / Print False False 1 7.000000 3.811869 Inches Default Swatch Group 0 White CMYK PROCESS 0.00000
%PDF-1.5 %���� 591 0 obj > endobj 702 0 obj >/Filter/FlateDecode/ID[ ]/Index[591 203]/Info 590 0 R/Length 347/Prev 2592437/Root 592 0 R/Size 794/Type/XRef/W[1 3 1]>>stream h��Ի/�Q����[�F %QM%�2H:�5.����� ��$UD��%batKL�Zl��f0�� #c'��J����.���� &o�F}����ye�� >stream hތ�]HSaǟ��w��nk�͏�/35 $& 2(8����������5����ώ�j�t��� ɐJ��( �C̻�u^FE����=[ s3z���?����_xx� �ہ�����rA ���}e�� �đ�1�X�tLpb���aJ�&�����u�"��s��9_��ü�oLů\6�Qz,N�S�r��OJ#���G�Ƨf� 3��S��ӧ�&g���sQ��Dz�� #4�j G`>iyc�K���K��a��Zk�&�"�t6v-��#Z�F�'�$�U�iiU�>w �SK��$f�����͖�E��6hL̛r��`�)\u endstream endob … �&i��E�Ȥ����?� ���-�+�2�F�����R��~�L}� endstream endobj 640 0 obj >stream application/postscript Print Daniel Elliott 2017-06-21T21:22:05+01:00 2017-06-21T21:22:05+01:00 2017-06-21T21:22:04+01:00 Adobe Illustrator CC 2015 (Macintosh) xmp.iid:6fd5c0ba-886c-4847-a42f-d9f2d2a03e85 xmp.did:6fd5c0ba-886c-4847-a42f-d9f2d2a03e85 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:1429a63f-381b-4bbe-b610-dcd92ca51b5b xmp.did:d92220c8-81e6-9646-85ef-ad1bfcf188fa uuid:5D20892493 … B PROCESS 129 53 138 Adobe PDF library 10.01 endstream endobj 641 0 obj >stream application/postscript Print Daniel Wentzell 2020-01-14T12:50:20Z 2020-01-14T12:50:20Z 2020-01-14T12:50:19Z Adobe Illustrator 24.0 (Macintosh) xmp.iid:7acf87fc-27ba-46c7-84ce-4753cd6c48ea xmp.did:7acf87fc-27ba-46c7-84ce-4753cd6c48ea uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:b4a3243c-90ec-4fe0-b46f-5a37ae35d18f xmp.did:b4a3243c-90ec-4fe0-b46f-5a37ae35d18f uuid:5D20892493BFDB11914A8590 … 019-09-06T14:36:52+01:00 Adobe Illustrator CC 23.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:b4a3243c-90ec-4fe0-b46f-5a37ae35d18f 2019-12-04T17:18:24Z Adobe Illustrator CC 23.0 (Macintosh) / con … 18f 2019-12-04T17:18:24Z Adobe Illustrator CC 23.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:7acf87fc-27ba-46c7-84ce-4753cd6c48ea 2020-01-14T12:50:20Z Adobe Illustrator 24.0 (Macintosh) / EmbedByReference /var/folders/wm/7rvd3nqs1yg_x26f8kgzlnt80000gp/T/TemporaryItems/(A Document Being
News Archives - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page Targeting protein misfolding in neurodegeneration by Jad Duncan | Mar 19, 2026 | News Origami Therapeutics CEO on harnessing autophagy to precisely target disease-causing proteins in the brain. Aptly-named US biotech Origami Therapeutics is working to redefine how neurodegenerative diseases are treated, building on the biological insight that many... What To Look For In Rare D
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Media - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page Media Media News Targeting protein misfolding in neurodegeneration Mar 19, 2026 | News Origami Therapeutics CEO on harnessing autophagy to precisely target disease-causing proteins in the brain. Aptly-named US biotech Origami Therapeutics is working to redefine how neurodegenerative diseases are treated, building on the biological insight that many... What To Look For In Rare Disease … most often is used in oncology. Now, Origami Therapeutics is among the first to apply it to genetic neurodegenerative disorders, targeting proteins that otherwise have been considered undruggable. Read full article Founder Spotlight #36: Beth Hoffman @ Origami Therapeutics Mar 21, 2022 | News Beth Hoffman is Founder, President, & CEO @ Origami Therapeutics. She brings more than 25 years experience of CNS drug discovery and has developed over 30 assets that have advanced i
Origami Therapeutics - 5th ALS Drug Development Summit 2026 Skip to content Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2027 event, please get in touch at [email protected] Returning June, 2027 | Boston, MA About About the ALS Drug Development Summit Events in the Series Hanson Wade CNS Products What’s On? 2026 Full Event Guide 2026 Speakers Why Partner Why Partner 2026 Partners Partnership Prospectus Take Part Register Interest Contact Us 2026 Event Guide Register Interest About About the ALS Drug Development
Our Technology - Origami Therapeutics Home About Us About Mission Leadership Team Advisory Board Our Science Protein Degradation Our Technology ORICISION™ Drug Discovery Platform Pipeline Careers Media Contact Select Page Our Technology Our Technology ORIGAMI Protein Degraders Origami is a pioneer of precision protein folding modulation – our founder was instrumental in the discovery of the first FDA-approved protein conformation correctors for Cystic Fibrosis. Our proprietary ORICISION™ platform enables discovery of both protein degraders and protein conformation correctors, allowing us